Sponsor study identifier
interventional
16
1 country
2
Study Start
October 2008
Date type not reportedThis date has not been verified as actual or estimated.
Primary Completion
July 2010
Actual (reported)Study Completion
July 2010
Actual (reported)BKT-140 drug substance is a highly selective chemokine receptor (CXCR4) antagonist, which is developed by Biokine as a novel therapy for Multiple Myeloma (MM, a type of blood cancer). The unique combination of activities of BKT140, i.e., the induction of the exit of blood cells such as stem cells and mature cells from the bone marrow to the peripheral blood, coupled with specific induction of MM cell death by BKT-140, represents a novel therapeutic strategy against MM.
Registry-reported information. Elapsed time and enrollment totals alone do not measure study progress or recruitment pace.
July 2010
Actual (reported)Click on a node to explore related trials.
Dates and qualifiers reported by the registry. Estimated dates do not confirm that a milestone has occurred.
October 2008
Date type not reportedThis date has not been verified as actual or estimated.
November 9, 2009
Actual (reported)November 10, 2009
Actual (reported)July 2010
Actual (reported)July 2010
Actual (reported)White blood cell (WBC) count
24 hour
CD34+ cells
24 hour
BKT-140 drug substance is a highly selective CXCR4 antagonist. BKT140 will be injected S.C once at dose of 0.03, 0.1, 0.3, 0.9 mg/kg
Department of Hematology and Bone Marrow Transplantation,Rambam Medical Center
Haifa, 31096, Israel
Chaim Sheba Medical Center,Tel-Hashomer
Ramat Gan, 52621, Israel
Abraham M, Biyder K, Begin M, Wald H, Weiss ID, Galun E, Nagler A, Peled A. Enhanced unique pattern of hematopoietic cell mobilization induced by the CXCR4 antagonist 4F-benzoyl-TN14003. Stem Cells. 2007 Sep;25(9):2158-66. doi: 10.1634/stemcells.2007-0161. Epub 2007 May 24.
Arnon Nagler, MD
Chaim Sheba Medical Center
First Submitted
November 9, 2009
First Posted
November 10, 2009
Study Start
October 2008
Date type not reportedThis date has not been verified as actual or estimated.
Primary Completion
July 2010
Actual (reported)Contact the study team to confirm eligibility.
Study Completion
July 2010
Actual (reported)Last Updated
June 10, 2011
Record last verified: 2011-06
Download the complete ClinicalTrials.gov record imported by Syfrah, including fields not shown in this page. The registry may contain a newer revision.
Source: ClinicalTrials.gov.
JSON downloads include source attribution and retrieval details alongside the unchanged original record or the separately normalized values.
Source retrieved: